One picture to understand Jiuyuan Gene (02566) 2025 annual performance: performance remains resilient, reinvest in research and development to enhance long-term competitiveness.

09:03 31/03/2026

In 2025, Jiuyuan Genetics (02566) achieved a revenue of 1.306 billion yuan and a net profit of 138 million yuan, with a corresponding net profit margin increasing by 0.5 percentage points year-on-year to 10.6%.

In 2025, Jiuyuan Gene (02566) achieved a revenue of 1.306 billion yuan and a net profit of 138 million yuan, with a corresponding net profit margin increasing by 0.5 percentage points to 10.6% year-on-year. While maintaining resilient performance, the company continues to invest in research and development to enhance its long-term competitiveness. Looking ahead, Jiuyuan Gene aims to transition from a strategy of "mimicry and breakthroughs" to "leading innovation and global expansion" while maintaining steady growth in its existing businesses. The company strives to become a leading domestic innovative biopharmaceutical company in the fields of oncology, hematology, orthopedics, and metabolic diseases with international competitiveness.

Huachuang Securities: Domestic retail industry transitions to a "goods looking for people" model, offline sector sees transformation opportunities towards a buyer's market.

HK Stock Market Move | China Tourism Group Duty Free Corporation (01880) surged over 5%, with a significant year-on-year increase in net profit in the fourth quarter of last year. The Hainan market has shown a strong recovery momentum.

GCL NEW ENERGY (00451) 2025 financial report: the value fusion and digital energy revolution under the loss figures.

Huachuang Securities: Domestic retail industry transitions to a "goods looking for people" model, offline sector sees transformation opportunities towards a buyer's market.

GCL NEW ENERGY (00451) 2025 financial report: the value fusion and digital energy revolution under the loss figures.